Dr. Veerle Verjans Nefroloog - Orpadt

Exenatide Effects on Diabetes, Obesity,
Cardiovascular Risk Factors, and Hepatic
Biomarkers in Patients with Type 2 Diabetes
Treated for at least 3 years
David C. Klonoff, MD, FACP 1 ; John B. Buse, MD, PhD 2 ; Loretta L. Nielsen, PhD 3 ;
Xuesong Guan, MS 3 ; Christopher L. Bowlus, MD 4 ; John H. Holcombe, MD 5 ;
Matthew E. Wintle, MD 3 ; David G. Maggs, MD 3 .
1 Diabetes Res Inst., Mills-Peninsula Hlth. Services, San Mateo, CA; 2 Division of
Endocrinology, Dept. of Medicine, Univ. North Carolina School Med., Chapel Hill,
NC; 3 Amylin Pharmaceuticals, Inc., San Diego, CA; 4 Univ. California-Davis, Davis,
CA; 5 Eli Lilly and Co., Indianapolis, IN.